PL3497104T3 - Postacie w stanie stałym soli ditosylanowej lumateperonu - Google Patents

Postacie w stanie stałym soli ditosylanowej lumateperonu

Info

Publication number
PL3497104T3
PL3497104T3 PL17754571T PL17754571T PL3497104T3 PL 3497104 T3 PL3497104 T3 PL 3497104T3 PL 17754571 T PL17754571 T PL 17754571T PL 17754571 T PL17754571 T PL 17754571T PL 3497104 T3 PL3497104 T3 PL 3497104T3
Authority
PL
Poland
Prior art keywords
lumateperone
solid state
state forms
ditosylate salt
ditosylate
Prior art date
Application number
PL17754571T
Other languages
English (en)
Inventor
Ariel Mittelman
Ido FUCHS
Sharona SHACHANTOV
Doron RUDIK
Rotem SELLA-EREZ
Original Assignee
Teva Pharmaceuticals International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59656224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3497104(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals International Gmbh filed Critical Teva Pharmaceuticals International Gmbh
Publication of PL3497104T3 publication Critical patent/PL3497104T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17754571T 2016-08-09 2017-08-08 Postacie w stanie stałym soli ditosylanowej lumateperonu PL3497104T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662372553P 2016-08-09 2016-08-09
US201662382479P 2016-09-01 2016-09-01
US201662382977P 2016-09-02 2016-09-02
US201662400358P 2016-09-27 2016-09-27
US201762486554P 2017-04-18 2017-04-18
PCT/US2017/045877 WO2018031535A1 (en) 2016-08-09 2017-08-08 Solid state forms of lumateperone ditosylate salt
EP17754571.2A EP3497104B1 (en) 2016-08-09 2017-08-08 Solid state forms of lumateperone ditosylate salt

Publications (1)

Publication Number Publication Date
PL3497104T3 true PL3497104T3 (pl) 2022-02-21

Family

ID=59656224

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17754571T PL3497104T3 (pl) 2016-08-09 2017-08-08 Postacie w stanie stałym soli ditosylanowej lumateperonu

Country Status (9)

Country Link
US (3) US11332469B2 (pl)
EP (2) EP4001281A1 (pl)
ES (1) ES2901375T3 (pl)
HR (1) HRP20211666T1 (pl)
HU (1) HUE057055T2 (pl)
IL (1) IL264521A (pl)
PL (1) PL3497104T3 (pl)
SI (1) SI3497104T1 (pl)
WO (1) WO2018031535A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
HUE057055T2 (hu) * 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
RS67906B1 (sr) * 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
AU2019328528B2 (en) * 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
WO2020123952A1 (en) * 2018-12-14 2020-06-18 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
KR20210104785A (ko) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
EP4134101A1 (en) * 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
WO2022195500A1 (en) * 2021-03-16 2022-09-22 Ami Organics Ltd. A process for the preparation of lumateperone tosylate intermediate
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN119585280A (zh) * 2022-07-30 2025-03-07 细胞内治疗公司 新的盐和晶体
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
CN118566395B (zh) * 2024-08-02 2024-10-25 则正(济南)生物科技有限公司 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
HUE057055T2 (hu) * 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
RS67906B1 (sr) 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof

Also Published As

Publication number Publication date
US11760757B2 (en) 2023-09-19
US20190211015A1 (en) 2019-07-11
HRP20211666T1 (hr) 2022-02-18
US20220127268A1 (en) 2022-04-28
EP3497104B1 (en) 2021-10-06
SI3497104T1 (sl) 2021-12-31
US11332469B2 (en) 2022-05-17
EP3497104A1 (en) 2019-06-19
ES2901375T3 (es) 2022-03-22
HUE057055T2 (hu) 2022-04-28
US20230382914A1 (en) 2023-11-30
WO2018031535A1 (en) 2018-02-15
IL264521A (en) 2019-05-30
EP4001281A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
IL264521A (en) Solid forms of lometaferon ditosylate
IL257026A (en) Solid state forms of eluxadoline
SG11201706729SA (en) Derivatives of sobetirome
SMT202100551T1 (it) Derivati di sobetirome
PT3466934T (pt) Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
IL265628A (en) Solid state forms of valbenazine
IL274627A (en) Solid forms of valbenazine
IL263853A (en) Solid state forms of palbociclib dimesylate
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
IL272670A (en) Preparation of micro-electrodes
SMT202000563T1 (it) Forem allo stato solido di sali di nilotinib
GB201701939D0 (en) Salt
IL263673A (en) Solid state forms of spiro-oxindole compounds
ZA201803035B (en) Biomarker of polycystic kidney disease and uses thereof
IL246569A0 (en) Solid forms of tenofovir
GB201602857D0 (en) Connection of rotatable parts
GB201600964D0 (en) Determination of vehicle capabilities
IL254666A0 (en) Crystalline forms of Aldecalcitol
HUP1500506A2 (en) Salts of palbociclib
GB201721386D0 (en) Chrondogy of time-wave
IL249332A0 (en) Crystalline forms of sofosbuvir